Primrose Bio is a groundbreaking brand that offers revolutionary products and tools, unlocking limitless possibilities in the discovery, development, and manufacture of new, complex molecules. With a merger between Primordial Genetics and Pelican Technology Holdings and $15 million in funding from Ligand Pharmaceuticals, Primrose Bio is set to make a significant impact in the industry.

Their team, consisting of experienced life sciences executives and entrepreneurs with over 150 years of combined experience, is dedicated to advancing global health. They enable the development of innovative therapeutics, vaccines, and manufacturing tools to improve and accelerate the way new biologics are conceived, developed, and commercialized.

Primrose Bio's Platform Technologies, including the Pfenex Expression Technology® and Function Generator™, provide cutting-edge solutions for protein expression, enzyme improvement, and synthetic biotechnology. They have a proven track record of success in producing novel proteins, enzymes, vaccine antigens, and more.

The brand offers a range of high-quality products, including CRM197 for marketed vaccines and Prima RNApols™ for mRNA-based vaccines and therapeutics. They also provide comprehensive offerings such as protein expression for human, animal, and industrial use, as well as nucleic acid-based therapeutics discovery and manufacturing.

With Primrose Bio, you can expect innovation, excellence, and a commitment to advancing global health through their groundbreaking products and services.